Psychemedics Corporation (PMD)

Market Cap	13.79M
Revenue (ttm)	20.26M
Net Income (ttm)	-3.00M
Shares Out	5.89M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,766
Open	2.330
Previous Close	2.320
Day's Range	2.321 - 2.350
52-Week Range	1.630 - 3.930
Beta	0.67
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About PMD

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabino...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: PMD
• Website: https://www.psychemedics.com

Financial Performance

In 2023, Psychemedics's revenue was $22.10 million, a decrease of -12.45% compared to the previous year's $25.24 million. Losses were -$4.15 million, 283.2% more than in 2022.